



Philanthropy Impact Report

2021-22

**Leukaemia
Foundation®**



Acknowledgement of Country

Budjeri Gamaruwa / Good day

My name is Matthew Doyle and I'm a Descendant of the Muruwari Nation from northwest NSW. I was born and raised on Gadigal land in Sydney. I would like to acknowledge all the Traditional Custodians of the land where the Leukaemia Foundation offices reside. On behalf of myself and the Leukaemia Foundation, we also pay our respects to all Elders past and present right across the nation and extend that respect to the people who take care of our loved ones in times of need.

As a person who's had personal experience with blood cancer, I'm delighted to join the Leukaemia Foundation as an ambassador. I look forward to creating more awareness and support around blood cancer for First Nations people and finding practical solutions.

Matthew Doyle
Ambassador
Leukaemia Foundation

A message of thanks from our Head of Philanthropy

Thank you for your loyal support of people living with blood cancer, their families and carers.

Our Philanthropy Team certainly missed being involved with our donors and prospective supporters in person over the past two years. At the end of the 2021-22 financial year, we slowly returned to coffee dates and meals together and enjoyed arranging our first lab and accommodation site tours without limiting numbers.

The recent past has taught us grace and acceptance. Our donors and partners have continued to grace us with their support and loyalty, which we have accepted with gratitude and humility. Philanthropy is the love of humankind demonstrated, something we've experienced in spades.

Thank you for joining us in our mission of zero lives to blood cancer by 2035. You've helped us achieve so many things, from supporting the careers of a new generation of researchers and clinicians with PhD Scholarships, through to improving the treatment outcomes and quality of life for blood cancer patients. You have advanced science by your investment in high-impact research.

This is my first Philanthropy Impact Report since joining the Leukaemia Foundation. Under the stewardship of a refreshed Board, I'm privileged to be part of a dynamic new leadership team guided by vision and purpose. At every level of our organisation, and with you, our most valued supporters, I have witnessed great empathy and compassion for those facing the devastating effects of blood cancer.

In this impact report, our Chair Lucio Di Giallonardo and our CEO Chris Tanti pay tribute to the real difference you have made to people affected by blood cancer. They chronicle their dream of a sustainable funding future, where the Leukaemia Foundation Endowment Fund and long-term philanthropic investment are truly transformational. We draw vital information from a landmark report delivered to us in 2022 that evaluates the wonderful impact of the Leukaemia Foundation over a five-year period. Our Board Director Nigel Harris, of Nigel Harris and Associates, writes from his heart about gratitude and service. Charlotte Webb, our General Manager Fundraising and Growth, honours the generosity of donors like you who stand in solidarity with us to help those whose lives have been impacted by blood cancer. There are many stories here of courage, survival and hope.

Please continue inviting us into your homes, gardens, towns, local cafes, and offices. We're so encouraged by your gracious hospitality and value the conversations and big questions as much as we value your financial generosity.

Our heartfelt thanks.



Jacqueline Williams
Head of Philanthropy
Leukaemia Foundation

A bold vision for a sustainable future

The unacceptable reality is that 53 Australians are diagnosed with blood cancer every day. This is projected to more than double by 2035.

Thanks to you, our generous community of supporters, the Leukaemia Foundation is at the forefront of delivering real, life-saving impact and advancing our shared goal of zero lives lost to blood cancer by 2035. With your support, we're moving closer each year, while fighting to meet the needs of every Australian living with blood cancer.

Over the last financial year, you've made an incredible difference to the lives of people facing blood cancer. Your generosity has funded breakthrough treatments and therapies and provided accommodation and transport services to those in need. Your gifts have alleviated financial burden and provided practical and emotional support for people as they navigate the difficult journey that begins with a blood cancer diagnosis. On these pages you will hear from those you have helped along with wonderful stories of philanthropy in action to affirm and inspire.

Our bold vision requires bold philanthropic partners like you. Therefore, I'm pleased to share this report, which highlights your crucial role in ensuring Leukaemia Foundation's funding future.

One strategic intent: four mission themes

As we continue to grow and extend our impact, we will be increasingly strategic in putting your investment to use, while always keeping our patients and their carers front of mind.

Globally, the charity sector is becoming increasingly competitive. Despite demonstrating a dramatically improved return on investment and being named the top cancer charity in Australia, we still need to innovate and be alert to opportunities for focus and deep impact.

Starting this financial year, we're asking major donors and partners to direct their support to four new mission themes. Naturally they incorporate the support services we are renowned for such as accommodation and practical support at the point of greatest need. They cover research in the broadest sense but we now also prioritise the careers of researchers to attract talent and foster an ecosystem around impactful blood cancer research. Finally, we are directing resources at survivorship: the clinical programs and services needed for wellbeing beyond treatment in order to thrive.

Our Philanthropy Team looks forward to talking with each of you to discover an interest in untied (unrestricted) or tied (restricted) giving and showing the real impact of your gift in delivering our mission priorities.

The Research Endowment Fund

The Leukaemia Foundation is committed to a measured and strategic approach to ensure investment in blood cancer research is truly impactful. To this end, we are prioritising growth of our Research Endowment Fund to sustainably deliver our long-term vision – a future where blood cancer no longer devastates lives.

The Research Endowment Fund was established in 2020 through generous seed funding gifts from the Frederiks Foundation and the Tony Fini Foundation. Additional funds were invested by the Leukaemia Foundation's share portfolio, accumulated over time from untied bequeathed estates.

To date, the Research Endowment Fund has underwritten strategic priorities such as PhD Scholarships. Further contributions to the Fund will be ring-fenced, with the earnings expended on mission-imperative activities when a solid corpus is secured.

Growing the Fund through strategic investment portfolios while redirecting income from other sources toward PhD Scholarships annually will remain a top priority. We are keenly aware that a mature fund is the best means to produce sustainable levels of income to make a real difference.

In 2025, the Leukaemia Foundation will celebrate its 50th anniversary. Our objective for the Research Endowment Fund in our milestone year is to raise a corpus of \$14 million – an ambitious target that can only be achieved with the support of you, our most generous and committed philanthropic partners.

The Leukaemia Foundation applauds your leadership in helping us to achieve our mission of stopping blood cancer from wrecking lives. We are truly grateful for your patronage. With so much to do to achieve our goals, we place great faith and trust in our special relationship.

We look forward to your continuing support.



Lucio Di Giallonardo
Chair of the Board
Leukaemia Foundation





Chris Tanti
CEO
Leukaemia Foundation

Your dedication and generosity directly affect people living with blood cancer

In the 2021-2022 financial year, overall fundraising revenue totalled **\$26,665,750**.

Within that amount, philanthropic gifts comprised **\$6,070,599** donated by **969** donors of which **\$2,674,023** were Gifts in Wills.



6,203 years

The Leukaemia Foundation deeply considers the impact of the work it does. But how do we measure impact?

Our scope of mission is complex and broad. Our community is diverse and encompasses the most vulnerable to the most powerful. What metrics matter to all?

To fulfill our commitment to transparency and to keep us on track for improvement, we commissioned some of the brightest economic minds in the country to measure the many ways we meet the needs of blood cancer patients and their carers.

Insight Economics measured the direct and indirects impacts of our work from the years 2015-2020 and presented their findings in 2022. The “Health, Social and Economic Impacts of the Leukaemia Foundation” is a report card to our generous supporters and the Australian community.

In the pages that follow, we share this record of our achievements with you. Your gifts helped us in ways you could not have imagined and the results in the report are simply astonishing.

You’ll see economic impacts clearly demonstrating sensible return on investment in dollar-terms. Social impacts are more difficult to quantify so stories from our community provide valid qualitative evidence. Health benefits are measured in the most beautiful, precious and universally understood metric of all: time.

It’s estimated that 6,203 precious years of life were gained for blood cancer patients between 2015-2020. Imagine the travel, the concerts, the beauty, the joy and the love you can give and receive in 6,203 precious years! That’s the real and tangible impact of your gift.



Policy Advocacy

The Leukaemia Foundation’s advocacy work is where we broaden the horizon for our ambitions and quietly achieve our most pervasive and lasting impacts.

The Leukaemia Foundation’s first State of the Nation Report in 2019 brought Australian governments and the blood cancer community together around a long-term plan to improve outcomes for people impacted by blood cancer. The Blood Cancer Task Force of committed partners followed and a bold vision for zero lives lost to blood cancer by 2035 was born.

The 2019 Report led to the development of the National Strategic Action Plan for Blood Cancer (NAP). Produced by a multi-disciplinary taskforce and championed by the Leukaemia Foundation, this systematic reform agenda means that all blood cancer patients could have timely and equitable access to best practice across all stages of the treatment journey. Experts have conservatively predicted that upwards of 15% of deaths can be prevented if this was consistent across Australia.

To date, there have been some impressive achievements:

- Six Optimal Care Plans have been developed to deliver consistent, safe, high-quality, evidence-based best care for people living with blood cancer. There are five more nearing completion.
- Access enabled for 19 new blood cancer therapies.
- Funding secured for Australia-wide clinical guidelines for blood cancer with a pilot currently underway.
- \$80 million funding from the Australian Commonwealth Government to establish Chimeric Antigen Receptor T-Cell (CAR-T cell) therapies in Australia.

- Two public-private partnerships were established in 2022 between the Australian Commonwealth Government and the Leukaemia Foundation. One to conduct a study into the epidemiology of blood cancer for First Nations people and the other to design a 10-year research roadmap to develop an ecosystem that accelerates breakthrough blood cancer research in Australia.

In economic terms, for every \$1 donated towards the realisation of goals for clinical best practice across Australia, \$3.90 of additional economic value was created. An amazing return on investment.



Research

Australian researchers are internationally renowned and our medical research institutions are recognised as world-class centres of excellence.

The Leukaemia Foundation has been a long-term funder of research in Australia. From 2000-2020, for every \$10 dollars of funding to the blood cancer research community, \$1 was provided by the Leukaemia Foundation.

In the 2015-2020 period, \$13.5 million has been invested in program grants (47%); PhD scholarships and Fellowships (37%); and clinical trials (20%). In the world of research, funding attracts funding. Programs funded by the Leukaemia Foundation have attracted an additional \$8 million from international industry and non-government organisations.

Combined, it is estimated that \$34.8 million of knowledge and productivity benefits would be generated in the long-term over the 2015-2040 period.

This means that for every \$1 the Leukaemia Foundation allocates to research funding, \$5.90 of additional value is added to the Australian economy.

The impact on health outcomes for recent and current research investment by the Leukaemia Foundation is not expected to be fully realised until 2035 but it is estimated to translate to more than 1,100 years of life. Further, by funding across a variety of programs and developing the ecosystem of research, the Leukaemia Foundation fosters a more open, networked research community.



Accommodation Services

Every time a patient avoids out of pocket expenses associated with accommodation stays for lifesaving treatment, this results in a direct increase to their household wealth.

Nearly half of patients self-funded their accommodation and a further 13% stayed with family and friends. Unfortunately, for a subset across these two groups (20%), it would increase their financial hardship. Research tells us this leads to poorer survival outcomes and the risk of progressing to long-term welfare payments.

Sadly, about five percent of patients would have declined treatment in the absence of accommodation. And a further 10% chose treatment centres closer to home that may not have been optimal. Over 20% would have stayed in hospital longer and this, counterintuitively, is associated with higher risks of infection and mortality, as well as depression. Not to mention the increase in demand on the hospital system.

Accommodation centres enhance access to transport services, financial assistance, information and psychosocial support. People make new friends and feel more connected to a supportive and understanding community.

In providing accommodation services 3,000 years of life were gained! Households saved \$11.5 million in expenditure and Australian governments saved \$148 million.



Financial Assistance

More than one in three Leukaemia Foundation patients reside in Australia's most socioeconomically disadvantaged areas.

Patients who would be at risk of reduced or lost employment, who do not have sufficient leave or leave options, have major repayments obligations (such as a home mortgage or a car) with limited savings are vulnerable to financial distress.

By supporting patients with direct financial assistance financial hardship can be avoided and we know that people experiencing poverty with poor social supports experience worse survival outcomes.

We are core supporters of people with high unmet needs and although the dollar value of financial assistance may seem small to many, the impact is considerable. 1,500 years of life were gained and Australian governments saved \$143 million in welfare payments.



Transport Assistance

Barriers to transport are complex and relate to multiple unmet financial and social need.

Research tells us that overall, between 10% and 51% of patients list transportation as a barrier to obtaining healthcare. It gets worse when you factor in socioeconomic disadvantage.

Most of us take our cars and our ability to drive them for granted. But more than 80% of people using our transport support services had no other option. Within that group, 15% required financial assistance and 10% had no carer or family support.

The unmet needs for some of our patients intersect and increase the likelihood of missed appointments, poor treatment adherence and becoming lost to follow up over time.

By providing transport assistance, blood cancer patients gained 381 years of life. Households saved \$6.4 million in expenditure and family and friends saved \$1 million worth of time.



Psychosocial Support Services

In the general population approximately 5% of people experience minor to severe depression. For cancer patients, this skyrockets to 35% with just under half categorised as severe. 10% of cancer patients are treated for anxiety with two thirds experiencing clinically significant levels. People living with blood cancer have the highest levels of anxiety for all cancers, with significant levels persisting for up to ten years. Again, for those with unmet socioeconomic needs, the rates of both depression and anxiety are even higher.

Psychosocial disorders reduce a person's capacity to cope with the burden of their disease and affects their adherence to recommended treatments. Without intervention, disorders don't just get better, they're more likely to get worse.

Nearly three quarters of patients and carers seeking psychosocial support services from the Leukaemia Foundation would not have sought them otherwise. We estimate a quarter of those would be experiencing high unmet socioeconomic needs, complicating matters further. By accessing support, the severity of depression and anxiety is reduced and it provides a mechanism to screen for suicide risk.

Psychosocial support services gave 222 years of life. Patients and carers avoided paying \$1.3 million in psychosocial services and Australian governments saved \$700,000.



Information and Education Services

Who do people trust for information about blood cancer and treatments? After the haematologist, the most common source of information for blood cancer patients and their carers was the Leukaemia Foundation.

In the 2015-2020 period, more than 40,000 direct patient engagement services were delivered to patients in the form of general support, information support and education seminars, at an average of more than 6,700 per annum, which equates to roughly 40% of the total blood cancer incidence.

With more than 70,000 booklets and one million page views per year, the Leukaemia Foundation empowers patients and their families with essential knowledge. That knowledge helps them navigate to the right service and care, potentially improving their survival outcomes.

It was estimated that the Leukaemia Foundation's information and education services earned \$1.1 million of productivity savings due to more efficient specialist consultation time. Put simply, patients were better-informed and able to engage more efficiently with their haematologist. It also has a bonus social effect of building community trust and connectedness through interactions with our blood cancer support coordinators.

Stellar Reputation

Finally, an impact metric of reputation and trust.

In 2023, RepTrak, a global leader of reputation data insights, named the Leukaemia Foundation as Australia's number one cancer charity and the third most reputable charity overall.

The RepTrak result is another objective data point to add to the impact reporting by Insight Economics. Together they provide further assurance to our generous donors of the value we deliver to individuals, families, and the broader Australian community.



Harnessing the power of T-cells

The multi-talented Dr Wei Jiang is both a scientist and an artist. She is a soprano, a violinist and one of Australia's brightest medical minds.

She was awarded a Leukaemia Foundation/Haematology Society of Australia and New Zealand PhD Scholarship in 2018. Her doctorate focused on developing T-cell immunotherapies, which involves genetically manipulating T-cells to make them into highly targeted therapies that seek and destroy blood cancer cells and eliminate infections.

For many blood cancer patients, bone marrow transplants are the only option for long term remission or cure. However, they come with significant complications and risks like graft vs host disease and infection. Together, these account for most transplant-related deaths.

People who have had a bone marrow transplant can have a compromised immune system, meaning common viral and fungal infections can be life threatening. During her PhD, Dr Jiang developed and trialled the use of T-cell immunotherapies targeted against a series of viruses and fungi commonly identified in people who have had a bone marrow transplant.

The outcomes of these trials were incredible, showing that these viral and fungal T-cell immunotherapies successfully treated the infections in 93% of patients on the trial.

Excitingly, Dr Jiang showed that she was able to use healthy donor cells to create these virus and fungal-specific T-cell immunotherapies. This means that pools of these T-cell immunotherapies can be made, stored and then used at short notice to treat transplant patients. Bespoke viral and fungal killing T-cells, off-the-shelf, available on-demand. Revolutionary.

Dr Jiang has published globally with five journal articles to date, over a dozen presentations at national and international conferences and symposia and has been recognised nationally with three awards for excellence.

Dr Jiang says that through this work, "We are impacting rates of relapse, overall survival, infection burden and quality of life of our patients".

Dr Wei Jiang, 2018 recipient of a Leukaemia Foundation/Haematology Society of Australia and New Zealand PhD Scholarship.



Oren fast-tracked to CAR T-cell therapy

Diagnosed with a rare ALL sub-type, Oren London had only just begun chemotherapy before being accepted for CAR T-cell therapy in Australia.

A sports-loving 12-year-old, Oren had competed in a state swimming championship and weekend rugby matches when his mum, Fiona Snell, noticed a series of changes in her son.

After three weeks of these symptoms, with no improvement, Fiona took Oren to their local doctor who sent them straight to hospital. After three hours of tests, the medical team told them that Oren had leukaemia. "That's when my whole world fell apart," said Fiona.

Oren and Fiona were medically transferred from the Tweed Hospital in northern New South Wales to Brisbane, so Oren could begin chemotherapy immediately for a confirmed diagnosis of acute lymphoblastic leukaemia (ALL). Oren faced many challenges – eventually preparations began for Oren to have a bone marrow transplant and he was set up to have full body radiation. Then, suddenly, Oren became a successful candidate for CAR T-cell therapy.

"Oren was the first child from Queensland Children's Hospital and the sixth child in Australia to have CAR T-cell treatment."

"I got my boy back. I now have my smiling, eating, walking, talking 16-year-old back."

After their experience, Fiona is keen to see CAR T-cell therapy become a frontline treatment for others diagnosed with childhood ALL.

"Research is progressing at such an impressive rate and I'm so thankful for all those people in the past that have been through the trials and testing to get CAR T-cell treatment to the place it is now."

Oren London, now in remission after receiving CAR T-cell therapy for ALL

Real impact: from people you have supported



Giles Purbrick:
Managing symptoms and a career

I found navigating work with chronic lymphocytic leukaemia (CLL) symptoms challenging, frustrating and sometimes exhausting.

Megan Moore and the Blood Cancer Support Coordinators have been a brilliant sounding board on career decisions during and after undergoing treatment for CLL, including providing expert and comprehensive support with my return to work strategy.



Peter Geary:
Helpful staff make all the difference

We stayed at the Leukaemia Foundation's Herston Village, close to the Royal Brisbane Hospital. Tania, our Blood Cancer Support Coordinator, and Sheila at the lodge were really helpful with advice and providing booklets for us to use for answering our questions regarding the transplant process.

In mid-December we returned to Herston Village where my wife Narelle stayed while I was in hospital for two weeks having the stem cell transplant and recovering.

During this time the staff at the Herston Village advised Narelle and assisted her as she is disabled. This support was greatly appreciated.

Tahlia Evans undergoing treatment as a toddler



Tahlia Evans:
Navigating my fertility journey

While I'm beyond grateful to have survived my childhood cancer, the side effects of my chemo caused a reduction in the growth of my ovaries and significantly lowered my egg count. Navigating my fertility journey has been difficult, but the support of the Leukaemia Foundation makes everything easier.

The information delivered in the Blood Cancer and Fertility webinar last year was immensely helpful as it provided many answers and explored this sensitive issue professionally and personally.

In the process of exploring and understanding the repercussions of treatment on my fertility, I'm blessed to have contact with a range of people from the Leukaemia Foundation who are able to point me in the direction of resources or listen with an empathetic ear.



A message of gratitude from our Board

When we talk about giving to the Leukaemia Foundation, we touch on several themes. The gift that is asked for and that which is given. The purpose and focus of the gift. The outcome and the impact that the gift will deliver.

One theme we also consider – but perhaps not always talk about – is how we and others feel about these gifts. A word that sums this up is gratitude, embracing the many elements associated with giving.

The Leukaemia Foundation is always deeply appreciative of your generosity. In this report, we hope to express this adequately and appropriately.

In expressing our gratitude to you, we're also doing so on behalf of those not always able to do so personally: the people with blood cancer whom the Leukaemia Foundation supports directly and indirectly, along with their families and friends.

Gratitude is described as a 'social glue' and commonly identified as a key to wellbeing. We're proud to play a small part in helping you express and experience this feeling of gratitude.



Nigel Harris AM
Board Director
Leukaemia Foundation

Inspiring philanthropy: in their own words



Greater Charitable Foundation

The Greater Bank's Greater Charitable Foundation was established in 2011 with a mandate to improve the life outcomes of families and communities throughout New South Wales and south-east Queensland.

In 2022, we launched a three-year \$252,450 partnership with the Leukaemia Foundation in support of their Financial Assistance Program. The program represents the essence of our current funding focus: to help improve the financial wellbeing of individuals and families.

Financial burdens are being alleviated for patients at a critical time in their health journey, providing a direct benefit, which is both practical and impactful.

Our Foundation also helps to facilitate employee volunteering activities in support of our charitable partners. One such recent activity was the World's Greatest Shave event at Greater Bank head office in Newcastle, which raised an additional \$14,000 for the Leukaemia Foundation.



The Tony Fini Foundation

If one has the opportunity or capacity to give, then do. It will make your soul sing because your contribution will help the Leukaemia Foundation achieve its goals.

The Leukaemia Foundation not only wants to stop people dying from blood cancer, but it also offers so many other services: accommodation for country people, advocating for more funding into blood cancer research, and lobbying the government to include treatments in the Pharmaceutical Benefits Scheme.

After several years of donating to the Leukaemia Foundation, we decided that we wanted our contribution to mean something more. We ultimately decided to support the Research Endowment Fund.

Research is essential to stop people from dying from blood cancer, opening the door for clinical trials and getting the newest and most effective treatments to patients sooner.



Peter Carr

In 2004, my doctor said, "There's something wrong with your blood tests."

It turned out to be Waldenstrom's Macroglobulinemia, a form of non-Hodgkin's Lymphoma. It's a rare blood disease and I found it really hard to find support organisations for people going through the same thing.

I eventually discovered an Australian support group call WMozzies, serving as a committee member for a time.

With the help of the Leukaemia Foundation, WMozzies organises support meetings. The demand for these surprised everyone – sometimes the rooms aren't big enough.

The work we're able to do with the Leukaemia Foundation is so important, not just for patients but for their carers and families too.

Anything you can do to extend this impact makes a life-changing difference.

Inspiring philanthropy: in their own words



Tour de Cure

In 2021, the Leukaemia Foundation and Tour de Cure co-funded a \$1.8 million Blood Cancer Genomics Trial in Queensland and South Australia. The program offers fresh hope to blood cancer patients, aiming to match their individual tumour profiles with available and promising treatments.

Tour de Cure has supported the Leukaemia Foundation since 2009 through its grants and Partnership Program. The two organisations share the same ethos of curing cancer and changing lives.

Supporting an organisation or funding a grant comes with the amazing knowledge that cancer research is advancing, and even contributing to a cancer breakthrough.

Organisations can make a real difference by funding the boldest research, the most talented scientists and world-class cancer projects.



Tim and Linda Goyder

A fundraising effort from Tim and Linda Goyder and their networks facilitated the expansion of the Blood Cancer Genomics Trial into Western Australia in 2022.

Tim (who was President of the Leukaemia Foundation Board in Western Australia for many years) says, “As someone who has lived with and survived blood cancer, I think it’s incredibly positive to see this potentially life-changing research now being undertaken here in Perth. I am hopeful this research can lead to better outcomes and survival rates.”

Dr Carolyn Grove is working on the Western Australian Blood Cancer Genomics Trial. She highlights, “Ongoing research has increased our understanding of the genetic complexity of blood cancer, which in turn has paved the way for new precision medicine-based therapies. This clinical trial will provide more Western Australian patients with access to new targeted treatments.”



Tom Shearer

I first learned of the work of the Leukaemia Foundation from my treating oncologist at the time. Dr Andrew Roberts suggested that I might like to assist the Leukaemia Foundation as it assists the welfare and dignity of blood cancer patients and their families.

My first donation to the Leukaemia Foundation was made shortly afterwards. In addition to annual giving, I have made provision in my Will that my estate will help provide good accommodation for cancer outpatients and spouses from the country or interstate, who otherwise might not be able to stay nearby during their treatment.

I feel that in partnership with the Leukaemia Foundation, a secure and kind helping hand has been extended firmly to people living with blood cancer.

My life is enriched by the privilege of being able to help.

A note of thanks from our Executive Leadership Team

In a world that remains increasingly complex, fast and fragmented, I remain in humbled awe by the consideration and generosity of our supporters. Those who stand beside us as we work to enable a future where blood cancer no longer wrecks lives.

Thank you all so much.



Charlotte Webb
General Manager
Fundraising and Growth
Leukaemia Foundation

With deep gratitude for your generous support

The Leukaemia Foundation would like to acknowledge those who so generously left a Gift in Will or made a leading donation this financial year. The following supporters have made a difference now and for the future. To all those who prefer to stay anonymous, we also say thank you.

Gifts in Wills

Norman Aldridge	Margaret MacLennan	Paolo Rubera
Daphne Annesley	Matheson Bequest	Ian Rylands
Hilda Atkins	Eva Maxwell	Colin Sampson
Shirley Lynette Ayres	Robert Maynard	Beverly Simersall
Nancy Baker	Agnes McDonnell	Eva Stastny
David Ball	Denise Lorrimer McGuire	Neil Stewart Memorial
Rozelle Barry	Beverly Joyce McIlwain	Endowment
Nola Bennett	Derek Martin Muller	Kevin Stuckings
Malcolm Bothwell	The Alf & Winifred Murgatroyd	Colleen Tatnell
Cecelia Brazil	Charitable Trust	Christine Julie Tighe
Joan Teresa Bremner	Thomas Edward Murray	Elsa Norma Vedder Trust
Bjorn Brolin	Daniel O'Dwyer	Lois Edna Wadham
Barbro Brolin	Margo Parry-McKittrick	Dulcie Jean Walker
Mary Cairns	Donald Reeves Paterson	Marie Glad Ward
Margaret Cameron	Vincent Pengilly	Ward Family Trust
Wendy Cavenagh	Nancy Hannah Dorothy	June F Weller
The Thomas and Vera	Penhallurick Fund	Thomas & Coral Williams
Condie Trust	Lorna Postle	Memorial Trust
Johanna Cronje	Malcolm Potter	David Miller Willis
Ian Neil Galletly	Ruth Louvain Pryce Trust	Clover Jessie Wilson
Roy Edmund Gaskin	Queensland Community	Rolf Woehler
Coralie Mavis Hartley	Foundation	John Raymond Yardley
Sybil Hine	Laurel Reece	James Peter Young
Lynette June Howden	Ivy Jane Reeves	Volker Zabo
Donald Christopher Hudson	Lynette Anne Richards	
Michael Kelleher	Mervyn Edwin Rodgers Fund	
Heather Maude King (Korber)	David Roleston	
Jens Letting	Margaret Roney	

Leading Donors

Megan Baker	Jonathan and Kaitlin Gumley	Jonathan O'Donohue
Boost Charitable Trust	Stephen and Sandra Gumley	Stan Perron Charitable
Phil and Pam Botsis and Family	Rae and Peter Gunn Family	Foundation
Bourne Foundation	Foundation	Bell Potter Securities Ltd
Calm Holdings Pty Ltd	Halifax Foundation	Pursche Foundation
Peter Carr	Hammond Family Foundation	Richardson Family Foundation
Civic Solutions	Handy Family Foundation	Bruce Saint
Cory Charitable Foundation	David Hill	Tom Shearer
Terry Cryer	Paul Hughes	Suitters Foundation
Davies Family Foundation	Lin Huddleston Charitable	Bert and Vera Thiess
Alfred and Jean Dickson	Foundation	Foundation
Foundation	John and Gay Hull	Anita Thomas
Rosalia Di Giacomo	John James Foundation	Tour de Cure Ltd
Tony Fini Foundation	Russell and Julie Kempnich	James and Danielle Unger
Mario and Maggie Franco	SN Kyri	The Universal Zone Pty Ltd
GKMI Pty Ltd	Nghia Quy Lam	Tony and Gai Wales
John and Paulette Goodell	Greg Lewins	William and Patricia Westlake
Tim and Linda Goyder	Todd Lewis	WMozzies
David and Macca Goyder	Val McAlpine	Rick Zeuschner
Greater Charitable Foundation	Dr Robert Menz	
Waverly Griggs	Ray Narkiewicz	

Blood Cancer Genomics Trial

We also acknowledge the following, including those who wish to remain anonymous, who helped expand the Blood Cancer Genomics Trial in Western Australia.

Ryan Armstrong	Mario and Maggie Franco	Walter and Robyn Unger
Chris Baker	Tim and Linda Goyder	The Universal Zone Pty Ltd
Craig Ball	David and Macca Goyder	Karl von Sanden
Barton Family Foundation	Richard Hacker	Michael and Amelia Walker
Phil and Pam Botsis and Family	Greg and Margaret Hackshaw	David Whiting
Calm Holdings Pty Ltd	Thomas Kenny	Michael Whiting
Roderick Clarkson	Hamish Nairn	Thomas Whiting
David Cutten	Mark Pittman	Craig Williams
Matthew Davies	Bell Potter Securities Ltd	Matthew Yates
Simon Doherty	James and Danielle Unger	

We thank each and every one of our wonderful donors all around the country. We acknowledge the overwhelmingly generous members of our blood cancer community who have also participated in and raised funds for various campaigns such as World's Greatest Shave, Light the Night, Dry July and DIY – fundraise your own way.

Your support is extending life and reimagining the future of blood cancer

We're beyond grateful to our community of leading supporters.

Throughout these pages, we have shown that your generosity is genuinely reshaping the future, forging a brighter tomorrow in which we conquer blood cancer.

Every gift makes a difference, unlocking unimaginable value for our community, advancing life-saving research and extending free support services to the 135,000 Australians living with blood cancer.

We hope you'll continue this journey with us, whether it's through a one-off or ongoing donation, a gift in your Will or focused philanthropy.

Contact us

Jacqueline Williams

Head of Philanthropy

E: philanthropy@leukaemia.org.au

Emma Dwyer

Gift in Wills Manager

E: edwyer@leukaemia.org.au

From left to right: Charlotte Webb, Emma Dwyer, Chris Tanti, Jacqueline Williams, Bruno Santarelli and Rebecca Barber.



“The hand is one of the oldest icons, a direct correspondence between imagination and execution. We extend a hand in gesture and service, we raise a hand as a pledge.”

– Patti Smith

**Leukaemia
Foundation®**

Mailing Address: GPO BOX 9954 BRISBANE QLD
Turrbal and Yuggera Country

The Leukaemia Foundation cares about our environment. Please recycle or dispose of thoughtfully.

ABN 57 057 493 017